Evaluating Topical Ruxolitinib Cream for Healing Ulcers in Adults with Pyoderma Gangrenosum
Led by Oregon Health and Science University · Updated on 2026-10-09
12
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
This research evaluates topical ruxolitinib cream as a treatment for adults with Pyoderma Gangrenosum PG, a rare, chronic inflammatory skin disease that causes painful ulcers. The study aims to determine if this topical medication helps heal ulcers completely without needing systemic immunosuppressive drugs. PG is commonly treated with systemic therapies that can have serious long-term side effects, so this trial explores a potentially safer topical option targeting the JAK-STAT pathway involved in the disease.
Participants will apply ruxolitinib 1.5% cream twice daily to the ulcer for 24 weeks while continuing their usual wound care, which may include cleansing, dressings, compression, and debridement as needed. No new systemic immunosuppressive treatments will be introduced during the study. After 24 weeks of treatment, those who respond well and remain safe may join a 48-week extension phase to continue using the cream under observation.
Throughout the 28-week study period, participants attend 10 visits including screening and follow-ups, some of which can be done via telemedicine if living far from the site. Assessments include skin exams, ultrasound imaging, blood tests for safety and infections, wound fluid analysis, and patient questionnaires on symptoms and quality of life. The main outcome measured is the complete healing of the target ulcer by Week 24, along with secondary measures like pain reduction, ulcer size change, and quality-of-life improvements. Safety and long-term effects will also be monitored.
CONDITIONS
Brief Title
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
Research Team
A
Alexandra Shinde, MSc
C
Chloe Vignola
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Topical ruxolitinib
Systemic immunosuppression
What it is
A single‑group study evaluating topical ruxolitinib 1.5% cream applied twice daily to a PG ulcer for up to 24 weeks
Systemic immunosuppressive therapy such as systemic corticosteroids, which are commonly used to treat PG ulcers
Role in study
Investigational therapy under evaluation
Not part of the trial but represents standard external practice
Primary purpose
To promote complete healing of PG ulcer over 24 weeks via topical application
To reduce inflammation and induce ulcer healing using systemic immune‑modulating agents
Administration / Use
Applied directly to the wound bed twice daily for up to 24 weeks
Administered systemically, typically oral corticosteroids, sometimes combined with other immunosuppressants
Evidence status
Evidence under investigation; trial results not yet available
Supported by case series, expert opinion and clinical reviews but lacks large randomized trial evidence
Important limitations
Limited to localized PG ulcer; single‑group design without direct comparator within trial
Lack of robust trial evidence and potential for serious systemic side effects
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 99Years
All Genders
Eligibility Criteria
You may qualify if you...
Willingness to comply with study procedures and requirements
Able to give informed consent
Diagnosis of at least one Pyoderma Gangrenosum ulcer with a maximum wound size of 10 cm²
Males aged 18 to 99 who agree to use effective birth control or abstain during the study and for 1 week after last dose
Females aged 18 to 99 who are non-childbearing or test negative for pregnancy and agree to use two reliable birth control methods or abstain during the study and for 1 week after last dose
Classic type of Pyoderma Gangrenosum with PARACELSUS score greater than 10
Candidates for topical therapy and may continue stable immunosuppression for comorbidities except potent immunosuppressants or JAK inhibitors
May be on stable prednisone dose of 10 mg or less
Undergoing at least weekly standard wound care at home or facility
Willing to travel for study visits or participate remotely if living more than 30 miles away with internet and webcam access
You will not qualify if you...
Having more than 3 ulcers with total area greater than 30 cm²
History or signs of malignancy or lymphoproliferative disease within 5 years
Active or recent certain skin cancers within 3 years
Active untreated infections or immunocompromised status posing unacceptable risk
Serious infection or intravenous antibiotics within 4 weeks before randomization
Active viral infections including HIV, hepatitis B or C, herpes zoster or herpes simplex
History of disseminated opportunistic infections
History or high risk for venous thromboembolism
Wound care debridement within 2 weeks before study
Previous use of systemic or topical JAK inhibitors
Significant drug or alcohol abuse within 6 months before baseline
Recent major surgery within 8 weeks before baseline or planned during study posing risk
Recent serious cardiovascular events or uncontrolled hypertension
Significant uncontrolled medical conditions or abnormal lab results posing risk
Women who are breastfeeding
Any condition interfering with study completion
Study personnel or immediate family members
Participation in other conflicting clinical trials within 4 weeks or 5 half-lives
Managing substance use disorder involving opioids or cannabinoids
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Treatment
Duration - 24 weeks
Participants apply topical ruxolitinib cream twice daily to the ulcer for 24 weeks while continuing standard wound care.
10 scheduled visits including some via telemedicine
Follow-up
Duration - 4 weeks after treatment
Participants are monitored up to 28 weeks with assessments and questionnaires to evaluate healing and safety.
Included in scheduled visits
Open-label Extension
Duration - Up to 48 weeks
Participants who respond well and remain safe may continue topical treatment for up to 48 additional weeks under observation.
Annual re-evaluations
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Evaluating SHR-1139 Injection for Adult Ulcerative Pyoderma Gangrenosum Patients Efficacy and Safety Study
Randomized, Double-Blind Study Evaluating Spesolimab Infusions for Treating Ulcerative Pyoderma Gangrenosum in Adults
Evaluating Topical Ruxolitinib Cream for Healing Ulcers in Adults with Pyoderma Gangrenosum
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Elaine C Siegfried, Jennifer C Jaworski, Jennifer D Kaiser...